Nanobiotix (NBTX) Projected to Post Earnings on Tuesday

Nanobiotix (NASDAQ:NBTX) is anticipated to post its H2 2025 results after the market closes on Tuesday, March 31st. Analysts expect Nanobiotix to post earnings of $0.2012 per share and revenue of $41.9520 million for the quarter. Parties may review the information on the company’s upcoming H2 2025 earning report for the latest details on the call scheduled for Thursday, April 2, 2026 at 11:40 AM ET.

Nanobiotix Price Performance

Shares of NASDAQ NBTX opened at $29.95 on Monday. The stock’s 50-day simple moving average is $27.23 and its 200-day simple moving average is $22.83. Nanobiotix has a fifty-two week low of $2.99 and a fifty-two week high of $41.89.

Analysts Set New Price Targets

Several brokerages have commented on NBTX. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Finally, Guggenheim increased their target price on shares of Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nanobiotix presently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Institutional Trading of Nanobiotix

A number of large investors have recently made changes to their positions in NBTX. Royal Bank of Canada increased its position in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares during the period. Marshall Wace LLP acquired a new stake in shares of Nanobiotix in the fourth quarter valued at approximately $220,000. Finally, Millennium Management LLC purchased a new position in shares of Nanobiotix during the fourth quarter worth approximately $390,000. 38.81% of the stock is owned by institutional investors and hedge funds.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.